MS Italian patients manifesting natalizumab-related PML between 2009 and 2014. Report of the Italian group for MS-PML study

被引：0

作者：

De Rossi, N. ^{[1
]}

Cordioli, C. ^{[1
]}

Gerevini, S. ^{[2
]}

Amato, M. P. ^{[3
]}

Bandini, F. ^{[4
]}

Cavalla, P. ^{[5
]}

Clerico, M. ^{[6
]}

Capobianco, M. ^{[7
]}

Deotto, L. ^{[8
]}

De Riz, M. A. ^{[9
]}

Ferrari, E. ^{[10
]}

Scarpazza, C. ^{[1
]}

Fusco, M. L. ^{[11
,12
]}

Ghezzi, A. ^{[13
]}

Grimaldi, L. ^{[14
]}

Lugaresi, A. ^{[15
]}

Moiola, L. ^{[16
]}

Perrone, P. ^{[17
,18
]}

Prosperini, L. ^{[19
]}

Rezzonico, M. ^{[20
]}

Rovaris, M. ^{[21
]}

Salemi, G. ^{[22
]}

Salvetti, M. ^{[23
,24
]}

Santuccio, G. ^{[25
]}

Solaro, C. ^{[26
]}

Tortorella, C. ^{[27
]}

Capra, R. ^{[1
]}

机构：

[1] Spedali Civili Brescia, Presidio Montichiari, Reg Multiple Sclerosis Ctr, Brescia, Italy

[2] Univ Milan, Osped San Raffaele, Serv Neuroradiol, Dipartimento Testa Collo, I-20127 Milan, Italy

[3] Dept NEUROFARBA, Sect Neurosci, Florence, Italy

[4] Osped San Paolo, SC Neurol, Savona, Italy

[5] AOU Citta Salute & Sci Torino V, Dipartimento Neurosci, Ctr SM, Turin, Italy

[6] AOU San Luigi Gonzaga Orbassano, Turin, Italy

[7] AOU, CRESM, Orbassano, Italy

[8] Azienda Osped Univ Integrata Verona, Dipartimento Attiv Integrata Neurosci, Unita Operat Complessa Neurol A, Verona, Italy

[9] Univ Milan, IRCCS Ca Granda Osped Maggiore Policlin, Ctr Sclerosi Multipla Padiglione Monteggia, Milan, Italy

[10] Ctr Osped Cremonese, Div Neurol, Cremona, Italy

[11] Univ Milano Bicocca, S Gerardo Hosp, Dept Neurol, Monza, Italy

[12] Univ Milano Bicocca, DNTB, Monza, Italy

[13] Azienda Osped S Antonio Abate, Ctr Studi Sclerosi Multipla, Direttore Neurol 2, Gallarate, Italy

[14] Fdn Ist San Raffaele G Giglio, Contrada Pietrapollastra Snc, Cefalu, Italy

[15] Univ G DAnnunzio, Dipartimento Neurosci, Imaging & Sci Clin, Chieti, Italy

[16] Univ Milan, Osped San Raffaele, Dipartimento Neurol, I-20127 Milan, Italy

[17] AO Osped Civile Legnano, Dipartimento Neuroscienze, Milan, Italy

[18] AO Osped Civile Legnano, UO Neurol, Stroke Unit, Milan, Italy

[19] Univ Roma La Sapienza, Dept Neurol & Psychiat, I-00185 Rome, Italy

[20] AO S Anna Como, Como, Italy

[21] Fdn Don Carlo Gnocchi, IRCCS Santa Maria Nascente, UO Riabilitaz Neuromotoria, Ctr Sclerosi Multipla, Milan, Italy

[22] Univ Palermo, Dipartimento Biomed Sperimentale & Neurosci Clin, Palermo, Italy

[23] Univ Roma La Sapienza, S Andrea Hosp, Ctr Expt Neurol Therapies CENTERS, Neurol, I-00185 Rome, Italy

[24] Univ Roma La Sapienza, S Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, I-00185 Rome, Italy

[25] Osped Civile, UO Neurol, Rome, Italy

[26] Unit ASL3 Genovese, Dept Head & Neck Neurol, Genoa, Italy

[27] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1146

引用

页码：596 / 597

页数：2

共 7 条

[1] Minimal supportive treatment in natalizumab-related PML in a MS patient
Lalive, Patrice H.
Bridel, Claire
Ferfoglia, Ruxandra Iancu
Kaiser, Laurent
Du Pasquier, Renaud
Barkhof, Frederik
Haller, Sven
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (03): : 354 - U184
[2] Natalizumab-Related Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) Italian Patients: Course, Outcome and Follow-Up
De Rossi, Nicola
Cardinli, Cinzia
Amato, Maria Pia
Gerevini, Simonetta
Clerico, Marinella
Deotto, Luciano
De Riz, Milena Alessandra
Scarpazza, Cristina
Fusco, Maria Letizia
Ghezzi, Angelo
Grimaldi, Luigi Maria
Grimaldi, Luigi Maria
Lugaresi, Alessandra
Moiola, Lucia
Perrone, Patrizia Susanna Mar
Prosperini, Luca
Rezzonico, Monica
Rovaris, Marco
Salemi, Giuseppe
Salvetti, Marco
Santuccio, Giuseppe
Tortorella, Carla
Capra, Ruggero
NEUROLOGY, 2016, 86
[3] Rituximab Treatment of Highly Active Multiple Sclerosis (MS) After Natalizumab-Related Progressive Multifocal Leukoencephalopathy (PML)
Cordioli, Cinzia
De Rossi, Nicola
Rasia, Sarah
Santuccio, Giuseppe
Capra, Ruggero
NEUROLOGY, 2016, 86
[4] Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
Lo Re M.
Capobianco M.
Ragonese P.
Realmuto S.
Malucchi S.
Berchialla P.
Salemi G.
Bertolotto A.
Neurology and Therapy, 2015, 4 (2) : 147 - 157
[5] The results of a controlled, prospective study of relapsing MS patients at risk for PML who switched from long term natalizumab to teriflunomide in a controlled, prospective study
Edwards, K.
O'Connor, J. T.
Siuta, J.
Thomas, J.
Cohan, S.
Smoot, K.
Kresa-Reahl, K.
Chen, C.
Gervasi, T.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 909 - 910
[6] The results of a 24-month controlled, prospective study of relapsing MS patients at risk for PML who switched from long term natalizumab to teriflunomide
Edwards, K.
O'Connor, J. T.
Siuta, J.
Cohan, S.
Smoot, K.
Kresa-Reahl, K.
Chen, C.
Gervasi, T.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 298 - 299
[7] Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
Santiago-Setien, Pilar
Barquin-Rego, Cristina
Hernandez-Martinez, Paula
Ezquerra-Marigomez, Maria
Torres-Barquin, Marta
Menendez-Garcia, Cristina
Uriarte, Fernando
Jimenez-Lopez, Yesica
Misiego, Mercedes
de la Torre, Jose Ramon Sanchez
Setien, Sonia
Delgado-Alvarado, Manuel
Riancho, Javier
FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 →